MSC2156119 is primarily investigated for its potential in cancer therapy, particularly in targeting and inhibiting specific pathways involved in tumor growth and proliferation. It shows promise in preclinical studies for treating various cancers, including those resistant to conventional therapies. The compound is being explored for its ability to enhance the efficacy of existing treatments when used in combination therapies. Researchers are also studying its pharmacokinetics and safety profile to determine its suitability for clinical trials. Its application extends to personalized medicine, where it may be tailored to patients based on genetic and molecular characteristics of their cancer.